756 results on '"Rosner, Gary"'
Search Results
52. Stroma-Free Human Hemoglobin A Decreases R3230Ac Rat Mammary Adenocarcinoma Blood Flow and Oxygen Partial Pressure
53. Bayesian Designs in Clinical Trials
54. S3. Methods for ellagic acid, urolithin A, quercetin, and resveratrol pharmacokinetics from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
55. S4. Supplementary Results: Prior ADT Treatment from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
56. Supplementary Figure S4.1 from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
57. Supplemental Figure 2 from A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan
58. Data from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
59. S1: MPX Manufacturing Process and Chemical Constituents from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
60. Supplemental Data from Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer
61. Supplemental Figure 1 from A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan
62. Supplemental Figures and Tables from A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
63. S2: Methods for SOD2 Genotyping and Validation from Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
64. Bayesian modelling of response to therapy and drug-sensitivity in acute lymphoblastic leukemia
65. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors
66. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
67. Additional file 1 of A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
68. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
69. Pharmacotypes across the Genomic Landscape of Pediatric Acute Lymphoblastic Leukemia and Impact on Treatment Response
70. Probability Modeling and Statistical Inference in Periodic Cancer Screening
71. INFERENCE OF LONG TERM EFFECTS AND OVERDIAGNOSIS IN PERIODIC CANCER SCREENING
72. Dose Individualization for High-dose anti-cancer Chemotherapy
73. Organ-Specific Differences in Gene Expression and Unigene Annotations Describing Source Material
74. ANOVA DDP Models: A Review
75. A Bayesian model with application for adaptive platform trials having temporal changes.
76. Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design
77. Bayesian Enrichment Strategies for Randomized Discontinuation Trials
78. Rejoinder
79. A Bayesian model with application for adaptive platform trials having temporal changes
80. Estimating the Term Structure With a Semiparametric Bayesian Hierarchical Model: An Application to Corporate Bonds
81. A Product Partition Model With Regression on Covariates
82. A Bayesian Approach to Dose–Response Assessment and Synergy and Its Application to In Vitro Dose–Response Studies
83. Semiparametric PK/PD Models
84. Bayesian Nonparametric Nonproportional Hazards Survival Modeling
85. Estimating Key Parameters in FOBT Screening for Colorectal Cancer
86. Bayesian Optimal Design for Phase II Screening Trials
87. A Semiparametric Bayesian Model for Repeatedly Repeated Binary Outcomes
88. Simple, Defensible Sample Sizes Based on Cost Efficiency
89. Sojourn time and lead time projection in lung cancer screening
90. YIA22-007: Adaptive Nutrition and Exercise Weight loss (A-NEW) Study for Breast Cancer Survivors With Overweight or Obesity
91. Advances in Statistical Approaches to Oncology Drug Development
92. An ANOVA Model for Dependent Random Measures
93. Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
94. A Phase I Study of Muscadine Grape Skin Extract in Men With Biochemically Recurrent Prostate Cancer: Safety, Tolerability, and Dose Determination
95. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome–negative acute lymphocytic leukemia
96. A projection of benefits due to fecal occult blood test for colorectal cancer
97. Exact Confidence Intervals Following a Group Sequential Trial: A Comparison of Methods
98. Group Sequential Tests with Censored Survival Data Adjusting for Covariates
99. Effects of the Calcium Channel Blocker Flunarizine on the Hemodynamics and Oxygenation of Tumor Microvasculature
100. Effects of Bradykinin on the Hemodynamics of Tumor and Granulating Normal Tissue Microvasculature
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.